Director, Upstream Product Marketing – Late Stage PSMA

ARTMS specializes in the physics, chemistry and materials science of cyclotron-produced radionuclides. Our core technology platform, the QUANTM Irradiation SystemTM (QISTM), is a complete cyclotron-based isotope production system designed to support high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu). QISTM is used today by many of the major manufacturing networks to optimize production of a range of medical radioisotopes. ARTMS has been acquired by Telix Pharmaceuticals. Interested in joining the team? Search our open positions: https://telixpharma.com/careers/find-a-job/